ClinicalTrials.Veeva

Menu

New Preservative-free Combination of Trehalose, Sodium Hyaluronate and N-acetyl-aspartyl-glutamate (NAAGA) in Dry Eye

Thea Pharma logo

Thea Pharma

Status and phase

Begins enrollment in 1 month
Phase 4

Conditions

Dry Eye Disease (DED)

Treatments

Device: T2769

Study type

Interventional

Funder types

Industry

Identifiers

NCT06903741
LT2769-006

Details and patient eligibility

About

The goal of this prospective, non-randomized, non-comparative, monocentric PMCF study is to assess the performance of a new preservative-free combination of trehalose, sodium hyaluronate and NAAGA on DED at 6 months in 30 patients having dry eye disease.

The main questions it aims to answer are:

  • To assess the performance and safety of T2769 at 3 months and 6 months.
  • To assess patient compliance to therapy.
  • To assess the occurrence of dry eye flares. Participants will be asked to use T2769 on a daily basis and complete a self-questionnaire throughout the study.

Enrollment

30 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Men and women aged over 18 years,
  • Able to give written informed consent prior the initiation of any procedure,
  • History of dry eye syndrome for at least 3 months,
  • OSDI ≥13,
  • Never been treated with artificial tears or with no artificial tears at least 1 month before the enrolment, or not satisfied with current artificial tears.

Exclusion criteria

Systemic/non Ophthalmic Exclusion Criteria

  • Known or suspected hypersensitivity to one of the components of the IMD,
  • History of or active relevant systemic condition incompatible with the investigation or likely to interfere with the investigation results or the patient safety according to investigator judgment.

Specific Exclusion Criteria Regarding Childbearing Potential Women

  • Pregnant or breast-feeding women,
  • Childbearing potential women neither surgically sterilised nor using an adequate contraception (oral contraceptive, intra-uterine device, subcutaneous contraceptive implant, vaginal ring, patch) .

Exclusion Criteria Related to General Conditions

  • Alcohol addiction and heavy smoker according to investigator's judgement,
  • Unable to understand the investigation procedures or to give informed consent,
  • Non-compliant (e.g., not willing to attend a visit or completing the self-questionnaire; way of life interfering with compliance),
  • Participant in this investigation at the same time as another clinical investigation/study,
  • Participant in this investigation within the exclusion period of a previous study/investigation with a minimum of one month,
  • Participant being institutionalized because of legal or regulatory order, inmate of psychiatric wards, prison or state institutions, or employee or family member of the investigation sites or of the Sponsor's company.

Exclusion criteria related to previous and concomitant treatments (medications/non-medicinal therapies/procedures)

• Participant with previous, current or anticipated prohibited listed treatment (or prohibited modification of treatment regimen).

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

30 participants in 1 patient group

Treated group
Experimental group
Description:
Groupe receiving T2769
Treatment:
Device: T2769

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems